25th August 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

*Refresh the page if the below document does not appear.

Delhi HC rules in Novartis' favour on its divisional patent application for a dry eye disease drug

Delhi High Court has overturned a Patent Office decision to reject Novartis AG’s application for a patent on a composition for the treatment of dry eye disease, and remanded the case back for further consideration of the divisional application’s merits.

Curatio to be acquired by Torrent Pharma

Torrent Pharmaceuticals,based in Ahmedabad, plans to purchase skincare product manufacturer Curatio Healthcare. Those with knowledge of the situation stated that the deal will value Curatio at $2,100 crore.

Formoterol Fumarate inhalation solution from Lupin receives USFDA approval

Lupin announced on Wednesday that USFDA had given its formoterol fumarate inhalation solution, used to treat the signs and symptoms of chronic obstructive pulmonary disease approval.

NPPA panel denies Intas' request for waiver of DPCO's requirements for clozapine ER capsules

National Pharmaceutical Pricing Authority’s expert panel has denied Intas Pharmaceuticals Ltd. ‘s request for an exemption from the requirements of the Drug Price Control Order 2013 for different strengths of its formulation of clozapine extended release (ER) capsules.

Pfizer outbid Johnson & Johnson in competing for Global Blood Therapeutics

Pfizer had to battle Johnson & Johnson before deciding on a $5.4 billion price tag for Global Blood Therapeutics. J&J initiated the negotiations by proactively approaching GBT with a buyout offer before Pfizer entered the picture.

Indian vaccine producers overtake MNCs in market share

For the first time, perhaps, indigenously manufactured vaccines have begun to take market share from MNCs in certain diseases, even as the Rs 3,000 crore private market fell by 15% month on month in June, one of the steepest such drops in recent years.

AstraZeneca's Soriot warns new drug price law in US will stifle innovation

CEO of AstraZeneca expressed concern about new legislation in the United States that would cap drug prices and limit companies’ ability to recover their investments in the development of new drugs.

PharmaState.academy offers easy access to training & up-skilling programs created by experts from Pharma Industry.

Welcome to PharmaState Academy

Install
×
Start chat
1
Need Help?
PharmaState Academy
Hello, how can we help you?